HighPoint Advisor Group LLC Has $1 Million Position in Bristol-Myers Squibb Co (BMY)

Share on StockTwits

HighPoint Advisor Group LLC boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 8.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,489 shares of the biopharmaceutical company’s stock after purchasing an additional 1,541 shares during the period. HighPoint Advisor Group LLC’s holdings in Bristol-Myers Squibb were worth $1,000,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Capital Financial Planning LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $28,000. Well Done LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $30,000. Riverview Trust Co acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $33,000. Portfolio Solutions LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $37,000. Finally, Gantzert Investment Co. LLC ADV acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $39,000. 74.27% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE:BMY opened at $45.57 on Monday. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69. The company has a quick ratio of 1.50, a current ratio of 1.61 and a debt-to-equity ratio of 0.40. The company has a market cap of $75.25 billion, a PE ratio of 11.45, a price-to-earnings-growth ratio of 2.37 and a beta of 0.79.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The company had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. During the same quarter in the previous year, the company earned $0.68 EPS. Bristol-Myers Squibb’s revenue was up 9.6% on a year-over-year basis. As a group, equities research analysts forecast that Bristol-Myers Squibb Co will post 4.16 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a dividend yield of 3.60%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.

BMY has been the subject of several research reports. BMO Capital Markets restated a “buy” rating and issued a $60.00 price objective on shares of Bristol-Myers Squibb in a research report on Thursday, January 3rd. Bank of America set a $53.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Friday, January 25th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Monday, April 8th. Morgan Stanley set a $54.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, December 20th. Finally, ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and six have assigned a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $59.13.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/4294179/highpoint-advisor-group-llc-has-1-million-position-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Featured Article: What is insider trading?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitchells & Butlers  Receives “Hold” Rating from Liberum Capital
Mitchells & Butlers Receives “Hold” Rating from Liberum Capital
Prudential  Given New GBX 2,300 Price Target at HSBC
Prudential Given New GBX 2,300 Price Target at HSBC
JPMorgan Chase & Co. Reaffirms Underweight Rating for Marks and Spencer Group
JPMorgan Chase & Co. Reaffirms Underweight Rating for Marks and Spencer Group
Symantec  Lifted to Sell at BidaskClub
Symantec Lifted to Sell at BidaskClub
Maxim Group Reaffirms Hold Rating for Pure Storage
Maxim Group Reaffirms Hold Rating for Pure Storage
Morgan Stanley Raises Sempra Energy  Price Target to $142.00
Morgan Stanley Raises Sempra Energy Price Target to $142.00


© 2006-2019 Ticker Report